Free Trial
NASDAQ:DTIL

Precision BioSciences Q2 2023 Earnings Report

Precision BioSciences logo
$5.02 +0.01 (+0.20%)
Closing price 04/17/2025 04:00 PM Eastern
Extended Trading
$5.03 +0.01 (+0.20%)
As of 04/17/2025 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precision BioSciences EPS Results

Actual EPS
-$3.00
Consensus EPS
-$6.90
Beat/Miss
Beat by +$3.90
One Year Ago EPS
N/A

Precision BioSciences Revenue Results

Actual Revenue
$19.79 million
Expected Revenue
$6.58 million
Beat/Miss
Beat by +$13.21 million
YoY Revenue Growth
N/A

Precision BioSciences Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Friday, August 4, 2023
Conference Call Time
12:00PM ET

Upcoming Earnings

Precision BioSciences' Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Precision BioSciences Earnings Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Precision BioSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Precision BioSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Precision BioSciences and other key companies, straight to your email.

About Precision BioSciences

Precision BioSciences (NASDAQ:DTIL), an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

View Precision BioSciences Profile

More Earnings Resources from MarketBeat